Form 4: Neumora Therapeutics Reprices Executive Stock Options, Lowering Exercise Price to $0.72

Neumora Therapeutics, Inc. (NMRA) has repriced stock options for its CEO and Chairman, Paul L. Berns, and other key personnel, significantly lowering the exercise price from $1.69 to $0.72 per share.

Summary

• On May 28, 2025, Neumora Therapeutics, Inc. (NMRA) stockholders approved the repricing of outstanding stock options.
• The repricing applies to options held by members of the Board, certain employees, and other service providers, including CEO and Chairman Paul L. Berns.
• The exercise price for these options was reduced from $1.69 per share to $0.72 per share.
• For Paul L. Berns, a total of 3,795,413 stock options were repriced, comprising four tranches: 497,049, 955,864, 342,500, and 2,000,000 shares.
• The repricing is contingent on Paul L. Berns remaining in service to the Issuer through August 13, 2026.
• All other terms of the options, including their respective vesting schedules and expiration dates, remain unchanged.
• Each option tranche vests over four years, with 25% vesting on the first anniversary of its Vesting Commencement Date and 1/48th of the total shares vesting monthly thereafter.

Sentiment

Score: 3

Explanation: The repricing of stock options, while re-incentivizing management, generally reflects past stock underperformance. It can be viewed negatively by existing shareholders due to potential dilution and the implication of a lower valuation. The retention aspect is positive, but the underlying reason for repricing is typically unfavorable.

Positives

• The repricing re-incentivizes key management and service providers, including the CEO, by making their stock options 'in-the-money' or closer to it, potentially aligning their interests more closely with future stock price appreciation.
• The condition that Paul L. Berns remains in service until August 13, 2026, provides a retention mechanism for a key executive.

Negatives

• Stock option repricing typically indicates that the company's stock price has fallen significantly below the original exercise price, suggesting past underperformance.
• The repricing could be viewed negatively by existing shareholders as it effectively grants new, more favorable options to insiders, potentially diluting the value of existing shares upon exercise.
• It may signal a lack of confidence in the stock's ability to recover to previous levels in the near term, necessitating a lower strike price to maintain incentive value.

Risks

• Potential for increased shareholder dilution if the repriced options are exercised, leading to an increase in the number of outstanding shares.
• Risk of management turnover if the condition for the repricing (Paul L. Berns remaining in service until August 13, 2026) is not met, although the repricing itself is designed to mitigate this.
• The repricing may be perceived by the market as a negative signal regarding the company's recent stock performance or future prospects, potentially impacting investor sentiment.

Future Outlook

The repricing of stock options is intended to re-incentivize key personnel, including the CEO, by lowering the exercise price, thereby making the options more valuable and aligning their future performance with potential stock price recovery and growth. The condition for the CEO's repriced options to be effective is continued service through August 13, 2026, indicating a focus on retaining key leadership for the near to medium term.

Management Comments

• Paul L. Berns holds the titles of Chief Executive Officer and Chairman of the Board.

Industry Context

Stock option repricing is a mechanism sometimes employed by companies, particularly in volatile sectors like biotechnology, when their stock price has significantly declined, rendering existing options 'underwater' and ineffective as an incentive. This action aims to restore the motivational value of equity compensation and retain key talent, although it can signal past stock underperformance.

Corporate Governance

Related Party Transactions

• The repricing of stock options for Paul L. Berns, who is the Chief Executive Officer and Chairman of the Board, constitutes a related party transaction as it involves a compensation adjustment for a key insider.

Stakeholder Impact

• Shareholders: Potential for future dilution if the repriced options are exercised, and the repricing itself may signal past stock underperformance. However, it could also lead to better management retention and motivation.
• Employees/Service Providers: Those whose options were repriced benefit from a lower exercise price, making their equity awards more valuable and providing renewed incentive.
• Management (Paul L. Berns): Benefits directly from the significantly reduced exercise price, re-establishing the incentive value of his stock options, contingent on continued service.

Next Steps

• Continued vesting of the repriced stock options according to their respective schedules.
• Potential exercise of the repriced options by Paul L. Berns and other beneficiaries, subject to vesting and market conditions.
• Paul L. Berns' continued service to the Issuer through August 13, 2026, to ensure the effectiveness of the repricing.

Key Dates

Recommendation

Keywords

Neumora Therapeutics, NMRA, Stock Options, Option Repricing, Executive Compensation, Insider Transaction, Form 4, Paul L. Berns, Corporate Governance, Equity Compensation